Background

Commercial prediction market platforms such as Kalshi and Polymarket are successively listing monetary contracts on whether primary endpoints of new drug development clinical trials are met or whether FDA approval is granted. The new drug R&D sector is characterized by high uncertainty, with clinical success rates typically around 10%, and key indicators have been trapped behind pharmaceutical companies' internal data or expensive paid analysis reports, leading to extreme information asymmetry. Proponents of prediction markets argue that combining collective intelligence with market mechanisms can rapidly aggregate scattered knowledge to derive success probabilities transparently. The logic is that quantifying complex scientific events into probabilities provides more agile signals than traditional analysis. However, the attempt to convert medical research, where human lives and treatment outcomes are at stake, into stakes for speculative financial products creates ethical repercussions on a completely different dimension from general financial markets.

Key Findings

In a paper published in the New England Journal of Medicine (NEJM), researcher Matthew Vogel and colleagues pointed out that the risk of undermining research integrity is far more serious than the information value provided by clinical trial prediction markets. A primary risk identified is the possibility of insider trading and data manipulation. Individuals with access to undisclosed clinical data before others—such as Clinical Research Organization (CRO) practitioners, clinical trial investigators, and members of Independent Data Monitoring Committees (DSMB)—may have incentives to leak interim results or undermine double-blind protocols for private gain.

The collapse of clinical equipoise is also a critical issue. Clinical trial ethics are maintained only when there is scientific uncertainty regarding whether the investigational drug is superior to the existing standard of care. If a prediction market reveals a figure approaching a 90% failure probability for a specific trial, patients are likely to refuse assignment to placebo or control groups and drop out of the trial. This ultimately hinders the completion of clinical trials and ensures reliability.

The 'false precision' created by predicted prices is also a cause for concern. Market contract prices fluctuate significantly due to lack of liquidity, rumors on social media, and price manipulation by small amounts of capital, rather than strict scientific data. Nevertheless, participants and the media are prone to misinterpreting the resulting prices as official statistical figures, leading to erroneous judgments.

Implications and Outlook

The researchers pointed out that the voluntary trust of patients participating in clinical trials collapses when their disease treatment process is treated like a casino gambling table. There is a significant concern that the pace of medical advancement itself may slow down as public skepticism toward scientific procedures grows. To prevent the infringement of research ethics obscured by the utility of information aggregation, strong institutional mechanisms must be in place.

Regulatory authorities, including the U.S. Commodity Futures Trading Commission (CFTC), must conduct a thorough pre-review of the public interest and manipulation risks associated with individual clinical prediction contracts. Another urgent task is to codify insider trading prevention regulations that strictly prohibit researchers and corporate insiders handling undisclosed clinical information from participating in the market. It is appropriate to fundamentally exclude small-scale clinical trials for rare diseases with low patient numbers, where conclusions can be altered by manipulating just a few results, from the list of products eligible for listing. Criteria should also be established to exclude evaluation metrics that are prone to subjective judgment. This is because the economic rationale of resolving information asymmetry must not undermine the fundamental principles of medicine, namely patient safety and scientific integrity.